Analyst Coverage
Stock price graph

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Repros Therapeutics Inc.'s financial performance into perspective.

Recent Releases

Nov 14, 2016
Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex® Delivered Orally and Vaginally for the Treatment of Uterine Fibroids

Nov 8, 2016
Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results

View all releases »

2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3446 fax